Table 5.

Reporting odd ratio of new signals of NSAIDs

Drug	Preferred terma	Number of reportsb	ROR	95% CI
Etoricoxib	oliguria	4	22.97	8.16–64.65
Parecoxib	cardiac arrest	4	15.53	5.77–41.79
Etoricoxib	pharyngeal edema	3	12.83	3.99–41.23
Sulindac	cheilitis	5	12.48	5.14–30.27
Etoricoxib	genital ulceration	10	8.94	4.74–16.85
Parecoxib	lacrimation increased	3	8.94	2.86–27.91
Celecoxib	hiccups	4	7.63	2.81–20.70
Parecoxib	choking	6	6.29	2.81–14.06
Ibuprofen	lacrimation increase	62	5.01	3.79–6.63
Diclofenac	laryngeal edema	5	4.41	1.73–11.26
Parecoxib	flushing	16	3.97	2.42–6.50
Etoricoxib	thermal burn	15	3.85	2.31–6.42
Celecoxib	choking	13	3.21	1.86–5.55
Diclofenac	lacrimation increase	24	2.68	1.77–4.07
Aspirin	choking	11	2.50	1.38–4.53
Ibuprofen	choking	83	2.08	1.66–2.61
Meloxicam	fixed eruption	96	2.05	1.67–2.51
Meloxicam	eczema	13	1.89	1.09–3.26
Mefenamic acid	fixed eruption	205	1.78	1.55–2.05
Etoricoxib	cheilitis	17	1.71	1.06–2.76
Mefenamic acid	anaesthesia oral	29	1.68	1.16–2.42
Etoricoxib	anaesthesia oral	20	1.67	1.07–2.60
Celecoxib	anaesthesia oral	19	1.64	1.04–2.58
Aspirin	fatigue	37	1.41	1.02–1.95

^aPreferred term of adverse events by the MedDRA coding system.

^bAll the reports containing NSAIDs that were identified as suspected or drug interaction were extracted from the Thai VigiBase, and each report may contain more than one event or drug.